RxDoctor Payments Data

Jay Doshi, MD

Cardiovascular Disease · Valhalla, NYNPI 1255596649

Payments from drug & device makers

$81,409in general payments, 2019–2025

Across 799 payments — averaging $101.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$57K
  • Biosense Webster, Inc.$8K
  • Biotronik Inc.$7K
  • Medtronic$2K
  • Boston Scientific$2K
  • Stereotaxis Inc$654
  • plus $5K from 38 others

What the payments were for

  • Consulting fees$1,7252%
  • Speaking & faculty fees$47,90061%
  • Travel & lodging$11,55715%
  • Food & beverage$17,56522%
  • Education$1170%
  • Entertainment$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,409 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$1,018,256
Medicare patients
554
Services billed
7,153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban381$372,402
MultaqDronedarone Hcl158$214,428
EntrestoSacubitril/Valsartan122$142,527
XareltoRivaroxaban73$88,235
VerquvoVericiguat42$40,973
FarxigaDapagliflozin Propanediol13$16,831
Repatha SureclickEvolocumab13$11,212
InpefaSotagliflozin17$10,961
Metoprolol Succinate447$5,311
Atorvastatin Calcium178$1,872
Ranolazine ErRanolazine18$1,778
Rosuvastatin Calcium104$1,493
Ezetimibe18$912
Diltiazem 24hr Er (Cd)Diltiazem Hcl27$625
Lisinopril139$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$561$372,402381 claims
Sanofi-aventis U.S. LLCMultaq$505$214,428158 claims
NovartisEntresto$280$142,527122 claims
Johnson & JohnsonXarelto$165$88,23573 claims
MerckVerquvo$408$40,97342 claims
AstraZenecaFarxiga$117$16,83113 claims
Lexicon Pharmaceuticals, Inc.Inpefa$277$10,96117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Valhalla

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →